Altre lingue Fulcrum Therapeutics, Inc.

Azioni

FULC

US3596161097

Tempo reale stimato Cboe BZX Altri mercati azionari 16:39:55 30/04/2024			Variaz. 5gg	Var. 1 gen.
7,1 ^USD	+0,28%		-4,03%	+5,78%

18/03	Fulcrum Therapeutics nomina Patrick Horn come Chief Medical Officer	MT
18/03	Fulcrum Therapeutics, Inc. annuncia cambiamenti esecutivi	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium	28/03
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	25/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22/03
Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	18/03
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18/03
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18/03
Fulcrum Therapeutics, Inc. Announces Executive Changes	18/03
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index	18/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference	05/03
GSK : la Dr Jeannie Lee entre au conseil d'administration	29/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	28/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27/02
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27/02
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET	20/02
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	08/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Fulcrum Therapeutics, Inc.

Azioni

FULC

US3596161097

Altre lingue

Filtri